echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Japan's first!

    Japan's first!

    • Last Update: 2022-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 19, Takeda announced that the new crown vaccine Nuvaxovid (NVX-CoV2373) has been approved for marketing in Japan for primary and booster immunizations of people 18 years of age and older


    NVX-CoV2373 was developed by Novavax and was first approved for marketing in the EU in December 2021


    The vaccine is an antigen derived from the new coronavirus spike protein and is used in conjunction with Matrix-M adjuvant (saponin-based adjuvant) to enhance the immune response and the production of neutralizing antibodies in the human body


    In June 2021, Novavax announced the results of two pivotal Phase III clinical trials of NVX-CoV2373 with excellent efficacy and safety data


    In addition, in response to the new crown epidemic, Takeda imported and distributed Moderna's mRNA vaccine Spikevax in Japan


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.